Sreenath V. Sharma

14.4k total citations · 3 hit papers
39 papers, 8.8k citations indexed

About

Sreenath V. Sharma is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sreenath V. Sharma has authored 39 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 16 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sreenath V. Sharma's work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Sreenath V. Sharma is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Sreenath V. Sharma collaborates with scholars based in United States, Japan and Switzerland. Sreenath V. Sharma's co-authors include Jeffrey Settleman, Daniel A. Haber, Daphne W. Bell, Jeff Settleman, Diana Lee, Ultan McDermott, Michael A. Fischbach, Marie Classon, Kwok‐Kin Wong and Hirofumi Nakano and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Sreenath V. Sharma

39 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidermal growth factor receptor mutations in lung cancer

2007 2.5k citations Sreenath V. Sharma, Daphne W. Bell et al. Nature reviews. Cancer profile →
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

2010 1.8k citations Sreenath V. Sharma, Diana Lee et al. profile →
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 774 citations Eunice L. Kwak, Raffaella Sordella et al. Proceedings of the National Academy of Sciences profile →

Peers

Sreenath V. Sharma

ONCOL

PRM

Carlos Garcı́a-Echeverrı́a Switzerland

Christine M. Lovly United States

Antonella De Luca Italy

Paul D. Smith United Kingdom

Suzanne F. Jones United States

Monica Mita United States

Paul T. Kirschmeier United States

Stephen R. Wedge United Kingdom

Tona M. Gilmer United States

Mathew J. Garnett United Kingdom

Carlos Garcı́a-Echeverrı́a Switzerland

Sreenath V. Sharma

6.7k ×1.2

2.9k ×0.7

ONCOL

1.3k ×0.4

PRM

1.1k ×0.7

869 ×1.5

Citations per year, relative to Sreenath V. Sharma Sreenath V. Sharma (= 1×) peers Carlos Garcı́a-Echeverrı́a

Countries citing papers authored by Sreenath V. Sharma

Since Specialization

Citations

This map shows the geographic impact of Sreenath V. Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sreenath V. Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sreenath V. Sharma more than expected).

Fields of papers citing papers by Sreenath V. Sharma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sreenath V. Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sreenath V. Sharma. The network helps show where Sreenath V. Sharma may publish in the future.

Co-authorship network of co-authors of Sreenath V. Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of Sreenath V. Sharma. A scholar is included among the top collaborators of Sreenath V. Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sreenath V. Sharma. Sreenath V. Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lantermann, Alexandra B., Dongshu Chen, Greg Hoffman, et al.. (2015). Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer. Cancer Research. 75(22). 4937–4948. 43 indexed citations

Sharma, Sreenath V., Daniel A. Haber, & Jeff Settleman. (2010). Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature reviews. Cancer. 10(4). 241–253. 441 indexed citations

Hassan, Amr, Sreenath V. Sharma, & Markus Warmuth. (2010). Allosteric inhibition of BCR-ABL. Cell Cycle. 9(18). 3734–3738. 23 indexed citations

McDermott, Ultan, A. John Iafrate, Shyamala Maheswaran, et al.. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Research. 69(9). 3937–3946. 83 indexed citations

Galimberti, Fabrizio, Xi Liu, Hua Li, et al.. (2009). Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe. Clinical Cancer Research. 16(1). 109–120. 60 indexed citations

Plentz, Ruben R., Andrew D. Rhim, Daniel L. Abravanel, et al.. (2009). Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology. 136(5). 1741–1749.e6. 132 indexed citations

Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861. 405 indexed citations

Sharma, Sreenath V. & Jeffrey Settleman. (2008). ErbBs in lung cancer. Experimental Cell Research. 315(4). 557–571. 53 indexed citations

Sharma, Sreenath V. & Jeffrey Settleman. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes & Development. 21(24). 3214–3231. 310 indexed citations

10.

Sharma, Sreenath V. & Jeffrey Settleman. (2006). “Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell. Cell Cycle. 5(24). 2878–2880. 26 indexed citations

11.

Kwak, Eunice L., Raffaella Sordella, Daphne W. Bell, et al.. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences. 102(21). 7665–7670. 774 indexed citations breakdown →

12.

Haber, Daniel A., Daphne W. Bell, Raffaella Sordella, et al.. (2005). Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology. 70(0). 419–426. 86 indexed citations

13.

Bell, Daphne W., Ira Gore, Ross A. Okimoto, et al.. (2005). Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics. 37(12). 1315–1316. 380 indexed citations

14.

Soga, Shiro, Yukimasa Shiotsu, Shiro Akinaga, & Sreenath V. Sharma. (2003). Development of Radicicol Analogues. Current Cancer Drug Targets. 3(5). 359–369. 100 indexed citations

15.

Oneyama, Chitose, Tsutomu Agatsuma, Yutaka Kanda, et al.. (2003). Synthetic Inhibitors of Proline-Rich Ligand-Mediated Protein-Protein Interaction. Chemistry & Biology. 10(5). 443–451. 37 indexed citations

16.

Asai, Akira, Tetsuya Tsujita, Sreenath V. Sharma, et al.. (2003). A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochemical Pharmacology. 67(2). 227–234. 72 indexed citations

17.

Oneyama, Chitose, Hirofumi Nakano, & Sreenath V. Sharma. (2002). UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug. Oncogene. 21(13). 2037–2050. 51 indexed citations

18.

Sharma, Sreenath V.. (1998). Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction. Oncogene. 17(3). 271–281. 35 indexed citations

19.

Soga, Shiro, Shiro Akinaga, Kenji Irie, et al.. (1998). Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-activated Aberrant Signaling Pathway. Journal of Biological Chemistry. 273(2). 822–828. 85 indexed citations

20.

Zhao, Jingfeng & Sreenath V. Sharma. (1995). Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genetics and Cytogenetics. 83(2). 148–154. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact